Therapeutic drug monitoring of intracellular anti-infective agents

Journal of Pharmaceutical and Biomedical Analysis

Volumn 101, Issue , 2014, Pages 183-193

  D'Avolio, Antonio ^a   Pensi, Debora ^a   Baietto, Lorena ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antibiotics; Antifungals; Antiretrovirals; Antivirals; Intracellular

Indexed keywords

ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POSACONAZOLE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT; VORICONAZOLE;

CELL COUNT; CELL VOLUME; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; CHEMISTRY; DOSE RESPONSE; MONONUCLEAR CELL; PROCEDURES;

ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; LEUKOCYTES, MONONUCLEAR;

EID: 84908318488     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.03.040     Document Type: Review

References (84)

1. Dollery C.T. Intracellular drug concentrations. Clin. Pharmacol. Ther. 2013, 93:263-266.
2. Bazzoli C., Jullien V., Le Tiec C., Rey E., Mentre F., Taburet A.M. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 2010, 49:17-45.
3. Molto J., Clotet B. Therapeutic drug monitoring of antiretroviral agents scenario. J. HIV Ther. 2004, 9:75-78.
4. Boffito M., Back D.J., Blaschke T.F., Rowland M., Bertz R.J., Gerber J.G., Miller V. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses 2003, 19:825-835.
5. Calcagno A., D'Avolio A., Simiele M., Cusato J., Rostagno R., Libanore V., Baietto L., Siccardi M., Bonora S., Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br. J. Clin. Pharmacol. 2012, 74:134-140.
6. Izzedine H., Hulot J.S., Villard E., Goyenvalle C., Dominguez S., Ghosn J., Valantin M.A., Lechat P., Deray A.G. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J. Infect. Dis. 2006, 194:1481-1491.
7. Kock K., Grube M., Jedlitschky G., Oevermann L., Siegmund W., Ritter C.A., Kroemer H.K. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin. Pharmacokinet. 2007, 46:449-470.
8. Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B.L., Keiser O., Biollaz J., Decosterd L., Telenti A. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 2005, 15:1-5.
9. Schipani A., Siccardi M., D'Avolio A., Baietto L., Simiele M., Bonora S., Rodriguez Novoa S., Cuenca L., Soriano V., Chierakul N., Saguenwong N., Chuchuttaworn C., Hoskins J.M., Dvorak A.M., McLeod H.L., Davies G., Khoo S., Back D.J., Di Perri G., Owen A. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob. Agents Chemother. 2010, 54:5242-5250.
10. Siccardi M., D'Avolio A., Baietto L., Gibbons S., Sciandra M., Colucci D., Bonora S., Khoo S., Back D.J., Di Perri G., Owen A. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis. 2008, 47:1222-1225.
11. Siccardi M., D'Avolio A., Nozza S., Simiele M., Baietto L., Stefani F.R., Moss D., Kwan W.S., Castagna A., Lazzarin A., Calcagno A., Bonora S., Back D., Di Perri G., Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet. Genomics 2011, 20:759-765.
12. Weiss J., Rose J., Storch C.H., Ketabi-Kiyanvash N., Sauer A., Haefeli W.E., Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 2007, 59:238-245.
13. Pan G., Giri N., Elmquist W.F. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab. Dispos. 2007, 35:1165-1173.
14. Ford J., Khoo S.H., Back D.J. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 2004, 54:982-990.
15. St-Pierre M.V., Ugele B., Gambling L., Shiverick K.T. Mechanisms of drug transfer across the human placenta-a workshop report. Placenta 2002, 23(Suppl. A):S159-S164.
16. D'Avolio A., Cusato J., Calcagno A., Di Perri G. Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?. J. Hepatol. 2013, 59:633-634.
17. Giraud C., Manceau S., Decleves X., Goffinet F., Morini J.P., Chappuy H., Batteux F., Chouzenoux S., Yousif S., Scherrmann J.M., Blanche S., Treluyer J.M. Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes. J. Clin. Pharmacol. 2009, 50:226-230.
18. Cropp C.D., Yee S.W., Giacomini K.M. Genetic variation in drug transporters in ethnic populations. Clin. Pharmacol. Ther. 2008, 84:412-416.
19. Varatharajan L., Thomas S.A. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009, 82:A99-A109.
20. Strazielle N., Belin M.F., Ghersi-Egea J.F. Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters. AIDS 2003, 17:1473-1485.
21. Stormer E., von Moltke L.L., Perloff M.D., Greenblatt D.J. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 2002, 19:1038-1045.
22. Almond L.M., Edirisinghe D., Dalton M., Bonington A., Back D.J., Khoo S.H. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin. Pharmacol. Ther. 2005, 78:132-142.
23. Doehring A., Hofmann W.P., Schlecker C., Zeuzem S., Sarrazin C., Berg T., Muller T., Herrmann E., Geisslinger G., Lotsch J. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenet. Genomics 2011, 21:289-296.
24. Fukuchi Y., Furihata T., Hashizume M., Iikura M., Chiba K. Characterization of ribavirin uptake systems in human hepatocytes. J. Hepatol. 2010, 52:486-492.
25. Ballesta S., Garcia I., Perea E.J., Pascual A. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 2005, 55:785-787.
26. Sun N., Li D., Fonzi W., Li X., Zhang L., Calderone R. Multidrug-resistant transporter mdr1p-mediated uptake of a novel antifungal compound. Antimicrob. Agents Chemother. 2013, 57:5931-5939.
27. Farowski F., Cornely O.A., Vehreschild J.J., Wiesen M., Steinbach A., Vehreschild M.J., Muller C. Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. Int. J. Antimicrob. Agents 2013, 41:379-382.
28. Tran Q.T., Mahendran K.R., Hajjar E., Ceccarelli M., Davin-Regli A., Winterhalter M., Weingart H., Pages J.M. Implication of porins in beta-lactam resistance of Providencia stuartii. J. Biol. Chem. 2010, 285:32273-32281.
29. Fass R.J., Barnishan J., Ayers L.W. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J. Antimicrob. Chemother. 1995, 36:343-353.
30. Bajaj H., Tran Q.T., Mahendran K.R., Nasrallah C., Colletier J.P., Davin-Regli A., Bolla J.M., Pages J.M., Winterhalter M. Antibiotic uptake through membrane channels: role of Providencia stuartii OmpPst1 porin in carbapenem resistance. Biochemistry 2012, 51:10244-10249.
31. Singh P.R., Ceccarelli M., Lovelle M., Winterhalter M., Mahendran K.R. Antibiotic permeation across the OmpF channel: modulation of the affinity site in the presence of magnesium. J. Phys. Chem. B 2012, 116:4433-4438.
32. Hartkoorn R.C., Chandler B., Owen A., Ward S.A., Bertel Squire S., Back D.J., Khoo S.H. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb.) 2007, 87:248-255.
33. Rey-Jurado E., Tudo G., Soy D., Gonzalez-Martin J. Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model. Int. J. Antimicrob. Agents 2013, 42:524-530.
34. Bushman L.R., Kiser J.J., Rower J.E., Klein B., Zheng J.H., Ray M.L., Anderson P.L. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J. Pharm. Biomed. Anal. 2011, 56:390-401.
35. Anderson P.L., Kakuda T.N., Kawle S., Fletcher C.V. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003, 17:2159-2168.
36. Moore J.D., Acosta E.P., Johnson V.A., Bassett R., Eron J.J., Fischl M.A., Long M.C., Kuritzkes D.R., Sommadossi J.P. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir. Ther. 2007, 12:981-986.
37. Fletcher C.V., Kawle S.P., Kakuda T.N., Anderson P.L., Weller D., Bushman L.R., Brundage R.C., Remmel R.P. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000, 14:2137-2144.
38. Durand-Gasselin L., Pruvost A., Dehee A., Vaudre G., Tabone M.D., Grassi J., Leverger G., Garbarg-Chenon A., Benech H., Dollfus C. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob. Agents Chemother. 2008, 52:2555-2563.
39. Stretcher B.N., Pesce A.J., Frame P.T., Stein D.S. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 1994, 38:1541-1547.
40. Aweeka F.T., Kang M., Yu J.Y., Lizak P., Alston B., Chung R.T. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092 Study Team. HIV Med. 2007, 8:288-294.
41. ter Heine R., Rosing H., van Gorp E.C., Mulder J.W., van der Steeg W.A., Beijnen J.H., Huitema A.D. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 867:205-212.
42. Ter Heine R., Mulder J.W., van Gorp E.C., Wagenaar J.F., Beijnen J.H., Huitema A.D. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br. J. Clin. Pharmacol. 2010, 69:475-483.
43. Nagano D., Araki T., Nakamura T., Yamamoto K. Determination of intracellular darunavir by liquid chromatography coupled with fluorescence detection. J. Chromatogr. Sci. 2013, Epub ahead of print.
44. Breilh D., Pellegrin I., Rouzes A., Berthoin K., Xuereb F., Budzinski H., Munck M., Fleury H.J., Saux M.C., Pellegrin J.L. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004, 18:1305-1310.
45. Lamotte C., Landman R., Peytavin G., Mentre F., Gerbe J., Brun-Vezinet F., Boue F., Spiridon G., Valantin M.A., Michelet C., Farinotti R., Yeni P. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antivir. Ther. 2004, 9:247-256.
46. D'Avolio A., Simiele M., Calcagno A., Siccardi M., Larovere G., Agati S., Baietto L., Cusato J., Tettoni M., Sciandra M., Trentini L., Di Perri G., Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J. Antimicrob. Chemother. 2013, 68:907-910.
47. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Oddone V., Stefani F.R., Agati S., Cusato J., Bonora S., Di Perri G. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J. Pharm. Biomed. Anal. 2011, 54:779-788.
48. Chaillou S., Durant J., Garraffo R., Georgenthum E., Roptin C., Clevenbergh P., Dunais B., Mondain V., Roger P.M., Dellamonica P. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin. Trials 2002, 3:493-501.
49. Homma M., Jayewardene A.L., Gambertoglio J., Aweeka F. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob. Agents Chemother. 1999, 43:2716-2719.
50. Inoue Y., Homma M., Matsuzaki Y., Shibata M., Matsumura T., Ito T., Mitamura K., Tanaka N., Kohda Y. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob. Agents Chemother. 2004, 48:3813-3816.
51. Kubota R., Komiyama T., Kumagai N., Kimijima M., Mitsuki K., Uetake J., Kaneko F., Tsunematsu S., Tsuchimoto K. Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection. Hepat. Res. Treat. 2010, 2010:495928.
52. D'Avolio A., De Nicolo A., Simiele M., Turini S., Agnesod D., Boglione L., Cusato J., Baietto L., Cariti G., Calcagno A., Sciandra M., Di Perri G., Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. J. Pharm. Biomed. Anal. 2012, 66:376-380.
53. Agnesod D., De Nicolo A., Simiele M., Mohamed Abdi A., Boglione L., Di Perri G., D'Avolio.A. Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. J. Pharm. Biomed. Anal. 2014, 90:119-126.
54. Farowski F., Cornely O.A., Vehreschild J.J., Hartmann P., Bauer T., Steinbach A., Ruping M.J., Muller C. Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 2010, 54:1815-1819.
55. Ashbee H.R., Barnes R.A., Johnson E.M., Richardson M.D., Gorton R., Hope W.W. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 2014, 69:1162-1176.
56. Pascual A., Garcia I., Conejo C., Perea E.J. Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 1993, 37:187-190.
57. Farowski F., Cornely O.A., Vehreschild J.J., Hartmann P., Bauer T., Steinbach A., Ruping M.J., Muller C. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob. Agents Chemother. 2010, 54:2928-2931.
58. Campoli P., Al Abdallah Q., Robitaille R., Solis N.V., Fielhaber J.A., Kristof A.S., Laverdiere M., Filler S.G., Sheppard D.C. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob. Agents Chemother. 2011, 55:5732-5739.
59. Conte J.E., Golden J.A., Krishna G., McIver M., Little E., Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 2009, 53:703-707.
60. Crandon J.L., Banevicius M.A., Fang A.F., Crownover P.H., Knauft R.F., Pope J.S., Russomanno J.H., Shore E., Nicolau D.P., Kuti J.L. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob. Agents Chemother. 2009, 53:5102-5107.
61. Wong G., Brinkman A., Benefield R.J., Carlier M., De Waele J.J., El Helali N., Frey O., Harbarth S., Huttner A., McWhinney B., Misset B., Pea F., Preisenberger J., Roberts M.S., Robertson T.A., Roehr A., Sime F.B., Taccone F.S., Ungerer J.P., Lipman J., Roberts J.A. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J. Antimicrob. Chemother. 2014, 69:1416-1423.
62. Pascual A., Ballesta S., Garcia I., Perea E.J. Uptake and intracellular activity of linezolid in human phagocytes and nonphagocytic cells. Antimicrob. Agents Chemother. 2002, 46:4013-4015.
63. Cappelletty D.M. Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy. Int. J. Antimicrob. Agents 2007, 29:212-216.
64. Hartkoorn R.C., Khoo S., Back D.J., Tjia J.F., Waitt C.J., Chaponda M., Davies G., Ardrey A., Ashleigh S., Ward S.A. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 857:76-82.
65. Becher F., Pruvost A., Goujard C., Guerreiro C., Delfraissy J.F., Grassi J., Benech H. Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2002, 16:555-565.
66. Farowski F., Cornely O.A., Vehreschild J.J., Bauer T., Hartmann P., Steinbach A., Vehreschild M.J., Scheid C., Muller C. Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood. Int. J. Antimicrob. Agents 2012, 39:228-231.
67. Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., Decosterd L.A. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2005, 819:259-276.
68. Pruvost A., Becher F., Bardouille P., Guerrero C., Creminon C., Delfraissy J.F., Goujard C., Grassi J., Benech H. Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2001, 15:1401-1408.
69. Compain S., Durand-Gasselin L., Grassi J., Benech H. Improved method to quantify intracellular zidovudine mono- and triphosphate in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. J. Mass Spectrom. 2007, 42:389-404.
70. Durand-Gasselin L., Da Silva D., Benech H., Pruvost A., Grassi J. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob. Agents Chemother. 2007, 51:2105-2111.
71. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006, 112:457-473.
72. Ho R.H., Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 2005, 78:260-277.
73. Benech H., Theodoro F., Herbet A., Page N., Schlemmer D., Pruvost A., Grassi J., Deverre J.R. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal. Biochem. 2004, 330:172-174.
74. Khoo S.H., Hoggard P.G., Williams I., Meaden E.R., Newton P., Wilkins E.G., Smith A., Tjia J.F., Lloyd J., Jones K., Beeching N., Carey P., Peters B., Back D.J. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob. Agents Chemother. 2002, 46:3228-3235.
75. Simiele M., D'Avolio A., Baietto L., Siccardi M., Sciandra M., Agati S., Cusato J., Bonora S., Di Perri G. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 2011, 55:2976-2978.
76. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 1994, 140:1-22.
77. Gao W.Y., Cara A., Gallo R.C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8925-8928.
78. Pruvost A., Theodoro F., Agrofoglio L., Negredo E., Benech H. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells. J. Mass Spectrom. 2008, 43:224-233.
79. Robbins B.L., Tran T.T., Pinkerton F.H., Akeb F., Guedj R., Grassi J., Lancaster D., Fridland A. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 1998, 42:2656-2660.
80. Stretcher B.N., Pesce A.J., Frame P.T., Greenberg K.A., Stein D.S. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994, 8:763-769.
81. Capron A., Lerut J., Latinne D., Rahier J., Haufroid V., Wallemacq P. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl. Int. 2012, 25:41-47.
82. Lemaitre F., Antignac M., Fernandez C. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. Clin. Biochem. 2013, 46:1538-1541.
83. Lemaitre F., Antignac M., Verdier M.C., Bellissant E., Fernandez C. Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going?. Pharmacol. Res. 2013, 74:109-112.
84. Brinkman K., Smeitink J.A., Romijn J.A., Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354:1112-1115.